Figures & data
Table 1 Patient characteristics at baseline
Table 2 Risk factors for disabling breathlessness in longitudinal analyses
Figure 1 Distribution of mMRC grades in the baseline COPD population.
Note: Percentages of patients with different mMRC grades in the baseline population (n=1,689).
Abbreviations: COPD, chronic obstructive pulmonary disease; mMRC, modified Medical Research Council.
![Figure 1 Distribution of mMRC grades in the baseline COPD population.Note: Percentages of patients with different mMRC grades in the baseline population (n=1,689).Abbreviations: COPD, chronic obstructive pulmonary disease; mMRC, modified Medical Research Council.](/cms/asset/234e144d-3296-4dca-aa41-afcb4350366a/dcop_a_119992_f0001_b.jpg)
Table 3 Persistent disabling breathlessness despite COPD treatment
Figure 3 Persistent disabling breathlessness (PDB) in treatment groups.
Note: Data presented as percentages of PDB in different treatment groups (n=1,689).
Abbreviations: LAMA, long-acting muscarinic antagonists; LABA, long-acting beta- 2-agonists; ICS, inhalation corticosteroids; LTOT, long-term oxygen therapy.
![Figure 3 Persistent disabling breathlessness (PDB) in treatment groups.Note: Data presented as percentages of PDB in different treatment groups (n=1,689).Abbreviations: LAMA, long-acting muscarinic antagonists; LABA, long-acting beta- 2-agonists; ICS, inhalation corticosteroids; LTOT, long-term oxygen therapy.](/cms/asset/06f13eb5-d745-494e-8670-20a7e1fc5497/dcop_a_119992_f0003_b.jpg)
Figure 4 Distribution of treatment groups within patients with persistent disabling breathlessness (PDB).
Abbreviations: LAMA, long-acting muscarinic antagonists; LABA, long-acting beta-2-agonists; ICS, inhalation corticosteroids; LTOT, long-term oxygen therapy.
![Figure 4 Distribution of treatment groups within patients with persistent disabling breathlessness (PDB).](/cms/asset/38208bdb-aaed-48c2-9354-0d8d100472f3/dcop_a_119992_f0004_b.jpg)
Table 4 Risk factors for change in disabling breathlessness over time